Wealth Enhancement Advisory Services LLC Purchases New Position in Progyny, Inc. (NASDAQ:PGNY)

Wealth Enhancement Advisory Services LLC acquired a new stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 15,855 shares of the company's stock, valued at approximately $354,000.

Several other institutional investors have also bought and sold shares of PGNY. SBI Securities Co. Ltd. purchased a new position in Progyny in the fourth quarter valued at approximately $74,000. Victory Capital Management Inc. lifted its stake in Progyny by 79.4% in the fourth quarter. Victory Capital Management Inc. now owns 203,277 shares of the company's stock valued at $3,507,000 after purchasing an additional 89,941 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Progyny by 129.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 19,967 shares of the company's stock valued at $344,000 after acquiring an additional 11,268 shares during the period. Amundi bought a new stake in Progyny during the 4th quarter valued at $102,000. Finally, River Road Asset Management LLC bought a new stake in Progyny during the 4th quarter valued at $25,529,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Stock Down 0.5%

NASDAQ:PGNY traded down $0.13 during midday trading on Thursday, hitting $23.66. The company had a trading volume of 312,672 shares, compared to its average volume of 1,713,653. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $30.42. The stock's fifty day moving average price is $21.79 and its 200-day moving average price is $21.41. The company has a market capitalization of $2.03 billion, a PE ratio of 41.38, a P/E/G ratio of 2.43 and a beta of 1.31.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a return on equity of 10.90% and a net margin of 4.33%. The company had revenue of $324.04 million during the quarter, compared to analysts' expectations of $307.86 million. During the same quarter last year, the firm posted $0.17 earnings per share. The firm's revenue was up 16.5% on a year-over-year basis. As a group, research analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insider Transactions at Progyny

In other Progyny news, Director Cheryl Scott sold 2,675 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total transaction of $59,037.25. Following the completion of the sale, the director directly owned 14,112 shares in the company, valued at $311,451.84. This represents a 15.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 9.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PGNY shares. Canaccord Genuity Group lowered their target price on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Leerink Partnrs raised shares of Progyny from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price target on the stock in a report on Tuesday. Finally, BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a report on Monday, March 31st. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $24.09.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.